Posted by Michael Wonder on 05 Jun 2024
Catalyst Pharmaceuticals receives US FDA approval for increased maximum daily dose for Firdapse
30 May 2024 - Catalyst Pharmaceuticals today announced that the US FDA has approved its supplemental new drug application increasing the indicated maximum daily dose of Firdapse (amifampridine) for adults and paediatric patients weighing more than 45 kg from 80 mg to 100 mg for the treatment of Lambert-Eaton myasthenic syndrome.
The increased maximum daily dose offers healthcare providers and patients greater flexibility in treatment regimens for the management of Lambert-Eaton myasthenic syndrome.
